Clinical trials: Retreatment, open to volunteers
Chronic Lymphocytic Leukemia (CLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration…
- Trial name
- ReVenG (NCT04895436)
- Testing
- Venetoclax, Obinutuzumab
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- AbbVie
Advanced Breast Cancer, Metastatic Breast Cancer
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to…
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
- Trial name
- DB-Guide (NCT07683754)
- Testing
- Trastuzumab deruxtecan, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Daiichi Sankyo
Recurrent Respiratory Papillomatosis, Papillomavirus Infection
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Trial name
- NCT06538480
- Testing
- Zopapogene imadenovec (Zopa)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Precigen, Inc
Chin Augmentation
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
- Trial name
- NCT07566286
- Testing
- Restylane Lyft with Lidocaine
- Where
- 8 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Flexible Hammertoe, Semi-flexible Hammertoe
Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)
The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.
- Trial name
- NCT07846280
- Testing
- KN3835
- Volunteers
- 470 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
CLL, Chronic Lymphocytic Leukemia
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab…
- Trial name
- CaDAnCe-302 (NCT06846671)
- Testing
- Tacabrutideg, Bendamustine, Idelalisib
- Where
- 132 sites in United States, Argentina and 12 more
- Volunteers
- 250 people
- Sponsor
- BeOne Medicines
Chronic Hepatitis B
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Studies have shown that chronic hepatitis B patients with low levels of HBsAg after nucleos(t)ide analog therapy have a higher chance of functional cure with sequential or combined pegylated interferon therapy, with about 30-50%…
- Trial name
- NCT06707922
- Testing
- Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
- Where
- 30 sites in China
- Volunteers
- 350 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
AAA - Abdominal Aortic Aneurysm, Aorta Aneurysm
Nectero EAST System Retreatment Study
This is an exploratory pilot study to evaluate the safety and clinical utility of retreatment with an investigational combination product called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.
- Conditions
- AAA - Abdominal Aortic Aneurysm, Aorta Aneurysm, Dilation Aorta
- Trial name
- NCT07505082
- Testing
- Nectero EAST System
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 10 people
- Sponsor
- Nectero Medical, Inc.